Kitty J. Jager

ORCID: 0000-0003-0444-8569
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dialysis and Renal Disease Management
  • Chronic Kidney Disease and Diabetes
  • Health Systems, Economic Evaluations, Quality of Life
  • Renal Transplantation Outcomes and Treatments
  • Organ Donation and Transplantation
  • Blood Pressure and Hypertension Studies
  • Renal and Vascular Pathologies
  • Healthcare Policy and Management
  • Central Venous Catheters and Hemodialysis
  • Healthcare cost, quality, practices
  • Renal Diseases and Glomerulopathies
  • Adolescent and Pediatric Healthcare
  • Organ Transplantation Techniques and Outcomes
  • Acute Kidney Injury Research
  • Pediatric Urology and Nephrology Studies
  • Statistical Methods in Clinical Trials
  • Meta-analysis and systematic reviews
  • Advanced Causal Inference Techniques
  • Chronic Disease Management Strategies
  • Global Health Care Issues
  • Pregnancy and Medication Impact
  • COVID-19 Clinical Research Studies
  • Frailty in Older Adults
  • Erythropoietin and Anemia Treatment
  • COVID-19 and healthcare impacts

Hôpital Necker-Enfants Malades
2025

Université Paris Cité
2025

Assistance Publique – Hôpitaux de Paris
2025

Inserm
2006-2025

Amsterdam University Medical Centers
2016-2025

University of Amsterdam
2016-2025

Public Health Service of Amsterdam
2018-2025

Amsterdam UMC Location University of Amsterdam
2015-2024

Leiden University Medical Center
2015-2024

Azienda ospedaliera "Bianchi-Melacrino-Morelli"
2024

Survival analyses are commonly applied to study death or other events of interest. In such analyses, so-called competing risks may form an important problem. A risk is event that either hinders the observation interest modifies chance this occurs. For example, when studying on dialysis, receiving a kidney transplant competes with Conventional methods for survival analysis ignoring event(s), as Kaplan–Meier method and standard Cox proportional hazards regression, be inappropriate in presence...

10.1093/ndt/gft355 article EN Nephrology Dialysis Transplantation 2013-08-24

CKD prevalence estimation is central to management and prevention planning at the population level. This study estimated in European adult general investigated international variation by age, sex, presence of diabetes, hypertension, obesity. We collected data from 19 general-population studies 13 countries. stages 1–5 was defined as eGFR<60 ml/min per 1.73 m 2 , calculated CKD-Epidemiology Collaboration equation, or albuminuria >30 mg/g, 3–5 . age- sex-standardized 27 Member States...

10.1681/asn.2015050542 article EN Journal of the American Society of Nephrology 2015-12-23

The aim of this study was to investigate 28-day mortality after COVID-19 diagnosis in the European kidney replacement therapy population. In addition, we determined role patient characteristics, treatment factors, and country on risk with use ERA-EDTA Registry data patients receiving Europe from February 1, 2020, April 30, 2020. Additional all a were collected 7 countries encompassing 4298 patients. COVID-19–attributable calculated using propensity score–matched historic control 28 days...

10.1016/j.kint.2020.09.006 article EN cc-by Kidney International 2020-10-15

In this article we introduce the concept of inverse probability treatment weighting (IPTW) and describe how method can be applied to adjust for measured confounding in observational research, illustrated by a clinical example from nephrology. IPTW involves two main steps. First, probability-or propensity-of being exposed risk factor or intervention interest is calculated, given an individual's characteristics (i.e. propensity score). Second, weights are calculated as score. The application...

10.1093/ckj/sfab158 article EN cc-by-nc Clinical Kidney Journal 2021-08-26

Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) group has produced comprehensive clinical practice guidelines for management of anaemia in CKD patients. These addressed all important points related to patients, including therapy with erythropoieis stimulating agents (ESA), iron therapy, ESA resistance and blood transfusion use. Because most were ‘soft’ rather than ‘strong’, because global need be adapted implemented into regional context where they are used, on behalf...

10.1093/ndt/gft033 article EN Nephrology Dialysis Transplantation 2013-04-12

10.1038/sj.ki.5002650 article EN publisher-specific-oa Kidney International 2007-10-31

One of the most common requests that statisticians get from investigators are sample size calculations or justifications. The is number patients other experimental units included in a study, and determining required to answer research question one first steps designing study. Although statistical textbooks describe techniques for calculation, it often difficult decide which method use. There many formulas available can be applied different types data study designs. However, all these should...

10.1093/ndt/gfp732 article EN Nephrology Dialysis Transplantation 2010-01-12
Luuk B. Hilbrands Raphaël Duivenvoorden Priya Vart Casper Franssen Marc H. Hemmelder and 95 more Kitty J. Jager Lyanne M. Kieneker Marlies Noordzij Michelle J. Pena Hanne de Vries David Arroyo Adrian Covic Marta Crespo Éric Goffin Mahmud İslam Ziad A. Massy Núria Montero João Oliveira Ana Roca Muñoz J. Emilio Sánchez-Álvarez Sivakumar Sridharan Rebecca Winzeler Ron T. Gansevoort Jeroen B. van der Net Marie Essig Peggy W G du Buf-Vereijken Betty van Ginneken Nanda Maas Liffert Vogt Brigit C. van Jaarsveld Fréderike J. Bemelman Farah Klingenberg-Salahova Frederiek Heenan‐Vos Marc G. Vervloet Azam Nurmohamed Daniel Abramowicz Sabine Verhofstede Omar Maoujoud Jana Fialová Edoardo Melilli Àlex Favà Josep M. Cruzado Joy Lips Maaike Hengst Ryszard Gellert Andrzej Rydzewski Daniela G Alferes Ivan Rychlík Elena Zakharova Patrice Max Ambuehl Fanny Lepeytre Clémentine Rabaté Guy Rostoker Sofia Marques Tijana Azasevac Dajana Katičić Marc ten Dam Thilo Krüger S. J. J. Logtenberg Lutz Fricke Adriaan L Zanen Jeroen J P Slebe Delphine Kemlin Jacqueline van de Wetering Jaromír Eiselt Lukáš Kielberger Hala S El-Wakil Samar Abd ElHafeez C Canal Carme Facundo Ana Ramos Alicja Dębska‐Ślizień Nicoline M H Veldhuizen Stylianos Panagoutsos Irina Matceac Ionuţ Nistor Monica Cordos J H M Groeneveld Marjolijn van Buren Fritz Diekmann Ana Cristina Fernandes Maria Ferreira Augusto César Soares dos Santos Carlos Arias-Cabrales Laura Llinàs-Mallol Anna Buxeda Carla Burballa Tàrrega Dolores Redondo‐Pachón María Dolores Arenas Jiménez Julia M. Hofstra Antonio Franco María Luisa Rodríguez-Ferrero Sagrario Balda Manzanos Gabriel de Arriba R. Haridian Sosa Barrios Karlijn Bartelet Erol Demir Daan A M J Hollander Angèle P. M. Kerckhoffs Stefan Büttner Aiko P. J. de Vries

Abstract Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available outcomes in this patient population. Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed transplant dialysis patients with COVID-19. For analysis, were included who presented...

10.1093/ndt/gfaa261 article EN other-oa Nephrology Dialysis Transplantation 2020-09-25

Abstract Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus 2019 (COVID-19) since the first report of in January 2020. However, this did not mention chronic kidney (CKD) nor it provide information on relevance estimated glomerular filtration rate (eGFR) or albuminuria. As spread across globe, larger populations with greater granularity emerged. The recently published OpenSAFELY project analysed associated COVID-19 death 17 million...

10.1093/ndt/gfaa314 article EN cc-by-nc Nephrology Dialysis Transplantation 2020-11-11

This article summarizes the ERA-EDTA Registry's 2016 Annual Report, by describing epidemiology of renal replacement therapy (RRT) for end-stage disease (ESRD) in within 36 countries.In 2017 and 2018, Registry received data on patients undergoing RRT ESRD from 52 national or regional registries. In all, 32 registries provided individual patient 20 aggregated data. The incidence prevalence survival probabilities these were determined.In 2016, was 121 per million population (pmp), ranging 29...

10.1093/ckj/sfz011 article EN cc-by-nc Clinical Kidney Journal 2019-01-11

Studies in cardiology often record the time to multiple disease events such as death, myocardial infarction, or hospitalization. Competing risks methods allow for analysis of first observed event and type event. They are also relevant if a specific is primary interest but competing may preclude its occurrence greatly alter chances observe it. We give non-technical overview concepts descriptive regression analyses. For statistics, cumulative incidence function most important tool. modelling,...

10.1093/eurheartj/ehu131 article EN cc-by-nc European Heart Journal 2014-04-07

Abstract Objective To determine the global capacity (availability, accessibility, quality, and affordability) to deliver kidney replacement therapy (dialysis transplantation) conservative management. Design International cross sectional survey. Setting Society of Nephrology (ISN) survey 182 countries from July September 2018. Participants Key stakeholders identified by ISN’s national regional leaders. Main outcome measures Markers core components Results Responses were received 160 (87.9%)...

10.1136/bmj.l5873 article EN cc-by-nc BMJ 2019-10-31

Congenital anomalies of the kidney and urinary tract (CAKUT) are leading cause ESRD in children, but proportion patients with individual CAKUT entities progressing to during adulthood their long-term clinical outcomes unknown. This study assessed age at onset renal replacement therapy (RRT) patient graft survival across entire range.Patients were compared age-matched who undergoing RRT for other disorders on basis data from European Renal Association-European Dialysis Transplant Association...

10.2215/cjn.03310412 article EN Clinical Journal of the American Society of Nephrology 2012-10-20
Coming Soon ...